OTCMKTS:AXIM AXIM Biotechnologies (AXIM) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free AXIM Stock Alerts $0.01 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.0090▼$0.012050-Day Range$0.0103▼$0.017652-Week Range$0.01▼$0.04Volume631,937 shsAverage Volume456,178 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get AXIM Biotechnologies alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About AXIM Biotechnologies Stock (OTCMKTS:AXIM)AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.Read More AXIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXIM Stock News HeadlinesApril 18, 2024 | seekingalpha.comADPT Adaptive Biotechnologies CorporationApril 4, 2024 | msn.comAxim youth appeal for sports infrastructureMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 27, 2024 | globenewswire.comVIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024March 7, 2024 | msn.comWe Want Peaceful Elections – Axim YouthFebruary 20, 2024 | finance.yahoo.comAXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical ValidationFebruary 20, 2024 | globenewswire.comAXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical ValidationFebruary 7, 2024 | msn.comAxim Fishermen Hail GovtMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.February 6, 2024 | msn.comMASLOC Trial: Daniel Axim Denies ChargesDecember 21, 2023 | msn.comAXIM and Auer partner for dry eye disease assay productionDecember 20, 2023 | finance.yahoo.comAXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay ProductionDecember 11, 2023 | msn.comTullow builds 14-unit dormitory block for Axim Girls SHSDecember 2, 2023 | seekingalpha.comLLBO Lifeline Biotechnologies, Inc.December 2, 2023 | seekingalpha.comCollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | msn.comCourt Orders Mental Test For Axim In MASLOC TrialNovember 1, 2023 | msn.comAxim Fishermen Plead For More PremixSeptember 12, 2023 | stockhouse.comAXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's DiseaseSeptember 12, 2023 | finance.yahoo.comAXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s DiseaseSeptember 10, 2023 | finance.yahoo.comAXIM - AXIM Biotechnologies, Inc.August 1, 2023 | finance.yahoo.comAXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody TestJuly 12, 2023 | finance.yahoo.comUpdate: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideJuly 12, 2023 | finance.yahoo.comUpdate: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideJuly 12, 2023 | finance.yahoo.comAXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideJune 14, 2023 | markets.businessinsider.comNV5's Newly Acquired Subsidiary Axim Pockets Contract From National Geospatial Intelligence AgencyMay 24, 2023 | finance.yahoo.comAXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform LaunchMay 23, 2023 | finance.yahoo.comAXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing UnitSee More Headlines Receive AXIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AXIM Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Next Earnings (Estimated)5/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AXIM CUSIPN/A CIK1514946 Webaximbiotech.com Phone(858) 923-4422FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. John W. Huemoeller II (Age 69)President, CEO & Director Comp: $420kMr. Robert T. Malasek (Age 56)CFO & Secretary Comp: $90kMs. Catalina Valencia J.D. (Age 75)Co-Founder & CEO of Sapphire Biotech, Inc. Comp: $187.5kMr. Kurt Phinney (Age 51)Chief Operating Officer Dr. Sergei A. Svarovsky M.B.A.Ph.D., Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc.Dr. Douglas Lake Ph.D.Chief Clinical Officer of Sapphire Biotech, Inc.Dr. Alim Seit-Nebi Ph.D.CTO & Co-Founder of Sapphire Biotech, Inc.Mr. Jeffrey A. BusbySenior Vice President of Business DevelopmentDr. Joseph Tauber M.D. (Age 67)Chief Medical Officer & Chairman of the Medical Advisory Board Dr. Maria J. Gonzalez Moa Ph.D.Vice President of Product Development - Sapphire Biotech, Inc.More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AXIM Stock Analysis - Frequently Asked Questions How have AXIM shares performed in 2024? AXIM Biotechnologies' stock was trading at $0.0190 on January 1st, 2024. Since then, AXIM shares have decreased by 42.1% and is now trading at $0.0110. View the best growth stocks for 2024 here. When is AXIM Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our AXIM earnings forecast. What other stocks do shareholders of AXIM Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other AXIM Biotechnologies investors own include Cronos Group (CRON), Tilray (TLRY), KushCo (KSHB), Curaleaf (CURLF), Charlotte's Web (CWBHF), Fulcrum Therapeutics (FULC) and Alibaba Group (BABA). How do I buy shares of AXIM Biotechnologies? Shares of AXIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AXIM) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AXIM Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
